Apellis Stock Performance

APLS
 Stock
  

USD 49.13  1.23  2.44%   

The firm shows a Beta (market volatility) of 0.3675, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Apellis's beta means in this case. As returns on the market increase, Apellis Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Apellis Pharmaceuticals will be expected to be smaller as well. Even though it is essential to pay attention to Apellis Pharmaceuticals historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy in foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Apellis Pharmaceuticals exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Apellis Pharmaceuticals has an expected return of -0.4%. Please be advised to confirm Apellis Pharmaceuticals maximum drawdown, and the relationship between the information ratio and expected short fall to decide if Apellis Pharmaceuticals performance from the past will be repeated at some point in the near future.
  
Apellis Performance
0 of 100
Over the last 90 days Apellis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's essential indicators remain relatively invariable which may send shares a bit higher in January 2023. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more

Apellis Price Channel

Begin Period Cash Flow567045000.00
Total Cashflows From Investing Activities247616000.00

Apellis Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  6,727  in Apellis Pharmaceuticals on September 10, 2022 and sell it today you would lose (1,814)  from holding Apellis Pharmaceuticals or give up 26.97% of portfolio value over 90 days. Apellis Pharmaceuticals is currently does not generate positive expected returns and assumes 4.2152% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Apellis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  
Given the investment horizon of 90 days Apellis Pharmaceuticals is expected to under-perform the market. In addition to that, the company is 2.83 times more volatile than its market benchmark. It trades about -0.1 of its total potential returns per unit of risk. The NYSE Composite is currently generating roughly 0.01 per unit of volatility.

Apellis Pharmaceuticals Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Apellis Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Apellis Pharmaceuticals, and traders can use it to determine the average amount a Apellis Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0952

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsAPLS
Estimated Market Risk
 4.22
  actual daily
 
 36 %
of total potential
 
3636
Expected Return
 -0.4
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.1
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Apellis Pharmaceuticals is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Apellis Pharmaceuticals by adding it to a well-diversified portfolio.

About Apellis Pharmaceuticals Performance

To evaluate Apellis Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Apellis Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Apellis Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Apellis Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Apellis's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Effect of Exchange Rate Changes on Cash-2 M-2.1 M
Return on Investment(112.77) (121.68) 
Return on Average Assets(81.02) (87.42) 
Return on Average Equity(370.20) (399.43) 
Return on Invested Capital(1.32) (1.35) 
Return on Sales(11.01) (11.30) 

Things to note about Apellis Pharmaceuticals

Checking the ongoing alerts about Apellis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Apellis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Apellis Pharmaceuticals Alerts

Equity Alerts and Improvement Suggestions

Apellis Pharmaceuticals generated a negative expected return over the last 90 days
Apellis Pharmaceuticals has high historical volatility and very poor performance
The company reported the previous year's revenue of 66.56 M. Net Loss for the year was (746.35 M) with loss before overhead, payroll, taxes, and interest of (253.92 M).
Apellis Pharmaceuticals currently holds about 852.8 M in cash with (563.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76.
Apellis Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Over 90.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Four Stocks to Play the Future of Healthcare Innovation - Barrons
Please continue to Trending Equities. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for analysis

When running Apellis Pharmaceuticals price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.6 B
Quarterly Revenue Growth YOY
2.904
Return On Assets
(0.46) 
Return On Equity
(5.07) 
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Apellis Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.